The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bang, Joon Seok | - |
dc.contributor.author | Lee, Jong Hyuk | - |
dc.date.accessioned | 2022-04-19T09:23:52Z | - |
dc.date.available | 2022-04-19T09:23:52Z | - |
dc.date.issued | 2021-04-03 | - |
dc.identifier.issn | 2167-8707 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/146663 | - |
dc.description.abstract | Introduction: In addition to some countries facing challenges regarding patients with rare diseases, it has also become an important international topic. Through the efforts of many nations around the world toward providing benefits for the development of orphan drugs to improve the right to treatment of patients with rare diseases, various orphan drugs have been launched in the market. However, controversial issues such as impact on budgets due to high prices and concerns about the uncertainty of clinical outcomes are being raised. For this review, the official websites of government agencies related to the Korean national health insurance were investigated. Areas covered: This paper reviews key factors that should be considered in the process of development, regulation, and market access of orphan drugs in South Korea with a particular focus on the pricing and reimbursement review process. Expert opinion: It is necessary to understand the pricing and reimbursement system of orphan drugs in terms of regulations and market access from the perspective of stakeholders, namely research and development companies, patients, policymakers, and physicians. Stakeholder discussions regarding value-based pricing methodologies such as new outcome-based ris-sharing agreement schemes and multi-criteria decision analysis should be conducted more prospectively. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1080/21678707.2021.1913121 | - |
dc.identifier.scopusid | 2-s2.0-85104327747 | - |
dc.identifier.wosid | 000639732800001 | - |
dc.identifier.bibliographicCitation | EXPERT OPINION ON ORPHAN DRUGS, v.9, no.4, pp 105 - 112 | - |
dc.citation.title | EXPERT OPINION ON ORPHAN DRUGS | - |
dc.citation.volume | 9 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 105 | - |
dc.citation.endPage | 112 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | PHARMACEUTICALS | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | ACCESS | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | Orphan drugs | - |
dc.subject.keywordAuthor | pricing and reimbursement | - |
dc.subject.keywordAuthor | rare disease | - |
dc.subject.keywordAuthor | national health insurance | - |
dc.subject.keywordAuthor | budget impact | - |
dc.subject.keywordAuthor | risk sharing | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/21678707.2021.1913121 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.